Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 4/20 | 0.69 |
| ▸ | JAK2 | O60674 | 4/20 | 0.61 |
| ▸ | IGF1R | P08069 | 8/20 | 0.54 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.47 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL519830 | 0.88 | JAK2 (0.66) | INSRJAK2IGF1RCDK4PLK4 | |
| SCHEMBL520616 | 0.87 | INSR (0.53) | INSRJAK2IGF1RALKCYP3A4 | |
| SCHEMBL519959 | 0.87 | ALK (0.69) | INSRJAK2IGF1RALKCYP3A4 | |
| SCHEMBL519464 | 0.82 | INSR (0.65) | INSRJAK2IGF1RALKSYK | |
| SCHEMBL519255 | 0.82 | ALK (0.53) | INSRJAK2ALKSYKCYP3A4 | |
| SCHEMBL520176 | 0.81 | INSR (1.00) | INSRJAK2IGF1RALKCYP3A4 | |
| SCHEMBL519278 | 0.81 | INSR (0.82) | INSRJAK2IGF1RALKSYK | |
| SCHEMBL520237 | 0.80 | INSR (0.61) | INSRJAK2IGF1RALKSYK | |
| SCHEMBL520723 | 0.79 | JAK2 (0.59) | INSRJAK2IGF1RALKCDK4 | |
| SCHEMBL519656 | 0.79 | INSR (0.69) | INSRJAK2IGF1RALKSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | INSR 1738/4885JAK2 1/4885IGF1R 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.